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Perspective
I
n the last decade or so, we 
have become familiar with the 
discovery of new classes of nuclear-
encoded regulators (see Glossary) 
as fundamental controllers of gene 
expression. Each new discovery has 
again highlighted the incomplete 
nature of our understanding of the 
genome and its regulation. First, 
small interfering RNAs (siRNAs) 
demonstrated that RNA molecules are 
not merely components of the cellular 
machinery (such as tRNAs and rRNAs) 
or gene-expression intermediates 
(mRNAs), but can function as 
potent trans-acting regulators of 
speciﬁ  c genes. MicroRNAs (miRNAs) 
continued this theme and now attract 
much attention among basic scientists 
and clinicians alike, both as potential 
regulators of most human genes and as 
potential diagnostic tools. In this issue 
of PLoS Medicine, a research article 
by Shigetada Teshima-Kondo and 
colleagues supports the suggestion that 
another class of regulatory RNAs exists 
[1]. Furthermore, this class could be 
the largest to date, since potential 
members are contained within every 
mRNA. 
A New Study on the 5' Non-Coding 
Region of VEGF mRNA
The authors show that the 5' 
untranslated region (UTR) of the 
vascular endothelial growth factor (VEGF) 
mRNA inﬂ  uences expression of other 
genes, and thereby cell function, 
independently of the VEGF reading 
frame. Many UTRs have long been 
known to function as cis-acting 
elements on the expression of their 
own mRNAs [2,3]—but trans-acting 
regulatory functions are an exciting 
possibility, which, if commonplace, 
would be every bit as inﬂ  uential as 
siRNAs or miRNAs.
VEGF is a key regulator of cancer 
development, acting to promote 
survival of tumour cells and to 
stimulate angiogenesis; as such, VEGF 
is well established as a target for cancer 
therapies [4]. The starting point for 
this new study was the observation that 
some uses of therapeutics targeting 
VEGF protein were less effective than 
might have been hoped [5]. The 
authors optimistically (but seemingly 
correctly) interpreted this observation 
as a suggestion that VEGF transcripts 
might have cancer-related functions 
separable from the functions of the 
VEGF protein, and set about further 
analyses. 
Working initially in tissue culture, 
the authors showed that VEGF 
promoted resistance to apoptosis 
(programmed cell death) induced by 
the chemotherapeutic 5-ﬂ  uoro-uracil. 
This was not surprising given VEGF’s 
familiar anti-apoptotic function [6]. 
However, in a thorough and detailed 
set of experiments, the authors also 
showed that expression of VEGF 
protein alone was insufﬁ  cient for 
the full anti-apoptotic effect seen, 
and furthermore, that expression of 
the VEGF 5'UTRs in isolation from 
the VEGF reading frame promoted 
signiﬁ  cant resistance. 
These experiments are especially 
complex since the VEGF 5'UTR is 
known to have a variety of cis-acting 
effects on translation of its reading 
frame [7]. Notably and unusually, 
translation can initiate from within the 
5'UTR at a number of CUG codons 
[8]. The authors have established that 
translation of sequences from within 
the UTR is not required to specify 
this apoptotic resistance, and thereby 
that the activity is truly associated 
with the RNA itself. Directing their 
attentions more towards a role for the 
VEGF 5'UTR in carcinogenesis, the 
authors showed that expression of the 
UTR, again without its reading frame, 
induced increased colony-forming 
activity in vitro, and tumour-forming 
ability in a mouse xenograft model. 
Finally, the authors established a link 
between expression of VEGF 5'UTR 
and a dramatic change in response to 
interferon alpha using both in vitro and 
in vivo models. The conclusion is that 
VEGF 5'UTR has independent tumour-
promoting activity, acting via mediators 
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Linked Research Article
This Perspective discusses the 
following new study published in PLoS 
Medicine:
Masuda K, Teshima-Kondo S, Mukaijo 
M, Yamagishi N, Nishikawa Y, et al. (2008) 
A novel tumor-promoting function 
residing in the 5’ non-coding region of 
vascular endothelial growth factor mRNA. 
PLoS Med 5(5): e94. doi:10.1371/journal.
pmed.0050094
Shigetada Teshima-Kondo and 
colleagues ﬁ  nd that cancer cells have 
a survival system that is regulated by 
vegf mRNA and that vegf mRNA and its 
protein may synergistically promote the 
malignancy of tumor cells.PLoS Medicine  |  www.plosmedicine.org 0698 May 2008  |  Volume 5  |  Issue 5  |  e110
of interferon alpha signalling, and 
therefore that the VEGF mRNA itself is 
oncogenic. 
Implications of the Study
While the idea that mRNAs might 
have functions that are independent 
of their translation may be surprising, 
there are published precedents for 
related trans-acting functions of UTRs. 
Such examples remain few and far 
between (Teshima-Kondo et al. cite 
four, and we have found a further two 
[9,10]) and have not had a signiﬁ  cant 
impact on the general consciousness of 
researchers. This new work represents 
an important advance, in that the 
function takes place in the context of 
a key player in carcinogenesis that is 
already used as a cancer therapy target, 
and therefore the study highlights this 
class of regulation. What this new study 
shares with its precedents, however, 
is the lack of a deﬁ  ned mechanism 
of action. As such it is difﬁ  cult to 
determine the generality of trans-acting 
functions of UTRs, and it is too early 
to start considering mRNAs as another 
class of fundamental gene regulators. 
How Do UTRs Exert Trans-Acting 
Inﬂ  uences?
It is possible to postulate a variety of 
mechanisms by which UTRs might 
exert trans-acting inﬂ  uences. First, the 
RNA-activated protein kinase (PKR) 
may be activated by binding to double-
stranded regions of UTRs. Activated 
PKR is well known to cause changes in 
the translational efﬁ  ciency of certain 
mRNAs as part of the cellular response 
to viral infection, but more recently 
has been implicated in other pathways, 
including cancer-related mitogen-
activated protein kinase signalling 
[11]. PKR has been shown to bind 
to one published trans-acting UTR 
[12], and Teshima-Kondo et al. report 
preliminary data (although these are 
not shown) indicating that PKR may 
bind to the VEGF mRNA. 
Alternatively, rather than activating 
a binding protein, trans-acting UTRs 
may sequester binding proteins away 
from other targets. In experiments 
where the UTR sequence has been 
over-expressed, as is the case for almost 
all these studies, this over-expression 
could allow artifactual effects, which 
is a concern for the physiological 
relevance of the observations. Some 
authors have speculated about UTR 
sequences making direct RNA:RNA 
interactions with target transcripts 
and thereby inﬂ  uencing their stability 
or translation. This mechanism is 
possible, but whether separate mRNA 
molecules, each of which would 
form its own mRNP structure, would 
have the opportunity to base-pair 
with each other with any signiﬁ  cant 
frequency seems debatable. Finally, 
for some 5'UTRs the trans-acting 
function appears to be dependent on 
translation of short upstream open 
reading frames (uORFs) within the 
UTR. The resultant peptides repress 
translation of other mRNAs, although 
seemingly only of those mRNAs 
arising from the same gene [9, 10]. 
Whether this peptide-mediated trans-
repression is truly this gene-speciﬁ  c 
remains to be determined. This ﬁ  nal 
proposed mechanism could provide 
an explanation for the trans-repression 
seen from the c-myc P0 5'UTR [13], 
which contains a uORF. However, it 
could not account for the inﬂ  uence of 
VEGF 5'UTRs, since Teshima-Kondo 
et al. demonstrate, at least in vitro, 
that their effect is maintained in the 
absence of signiﬁ  cant translation. 
Conclusion
This study has a clear implication 
for VEGF-targeted therapies, in that 
strategies to target the mRNA may be 
required to inhibit the full oncogenic 
inﬂ  uence of the gene. More generally, 
the study highlights a little-studied 
gene regulatory pathway that may yet 
prove to be far more commonplace 
than currently appreciated.  
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